克洛法齐明的药理动力学和安全性在患有耐利芬素结核病的儿童中
Jennifer A Hughes1, Belén P Solans2,3, Anthony J Garcia-Prats1,4
1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
The Journal of infectious diseases
|February 11, 2025
概括
对于儿童多药耐药结核病的克洛法齐明治疗导致药物暴露率高于成年人. 这种增加的暴露可能会带来风险,包括QT间隔延长,特别是与其他药物结合使用时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿童传染病 儿童传染病
- 结核病研究 结核病研究
背景情况:
- 多种药物/素耐药结核病 (MDR/RR-TB) 需要儿童有效的治疗选择.
- 克洛法齐明是MDR/RR-TB疗法中的关键药物,但其在儿科患者群体中的使用需要仔细的药理动力学和安全性评估.
- 了解儿童的克洛法西明暴露对于优化治疗和尽量减少不良事件至关重要.
研究的目的:
- 评估克洛法齐明在治疗MDR/RR-TB的儿童中的药理动力学.
- 在这个儿科队列中评估克洛法齐明的安全性.
- 为了比较儿科克洛法齐明暴露与已确立的成年目标.
主要方法:
- 一项涉及18岁以下儿童的药理动力学研究,这些儿童接受了基于体重的克洛法齐明剂量治疗.
- 在基线,第2周和第16周进行稀疏和半密集的血液采样,以确定氏胺在度-时间曲线 (wAUC) 下的每周面积.
- 安全监测包括QT间隔测量和实验室评估,并与成人wAUC目标进行比较.
主要成果:
- 这项研究包括20名儿童 (平均年龄为6.0岁).
- 与MDR/RR-TB的目标成年人wAUC相比,儿童中克洛法齐明的wAUC中位数显著更高 (超过25%).
- 没有发生严重的心脏事件,但观察到克洛法齐明度和QT间隔延长之间的积极关联;肝酶升高的一例导致暂时停用药物.
结论:
- 基于体重的小儿用克洛法齐明剂量导致药物暴露的程度远高于标准剂量的成年人.
- 增加的暴露和与之相关的QT间隔延长风险在儿童中需要谨慎,特别是在与其他QT延长剂同时使用时.
- 需要进行进一步的研究,以确定儿科MDR/RR-TB治疗的最佳和安全的克洛法齐明剂量策略.
相关概念视频
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
72
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
72
Pulmonary Tuberculosis I
220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Renal Failure: Dose Adjustments
60
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
60


